Novo Nordisk expects future research and development expenditures will increase at a higher rate than the company’s top line growth. This will ensure that one or more successors are ready once the pharmaceutical firm’s current growth engine, semaglutide, loses its patent.
As well as internal research, one eye will be fixed on potential acquisition candidates for Novo Nordisk. As late as December 2021, the Danish company bought US-based Dicerna for USD 3.3bn – the single biggest acquisition on Novo’s history.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Long wait for IVDR implementation is over, putting an end to pandemic "wild west"
After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26.
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Bavarian Nordic upgrades guidance following vaccine contract
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
US to start using Bavarian vaccine stockpile
In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease.
Client Talent Acquisition Specialist 
Project Manager & Scrum Master 
Consultant Manager 
Nordic Medical Affairs Manager 
SAP System Specialist (Product Supply) – Business Application Services 
Cell Culture Scientist/Senior Scientist 
IRT Manager, Clinical Drug Supply 
Senior Chemical Safety Advisor 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Director of Toxicology 
Production Director 
Clinical Trial Manager for development of in vitro diagnostics 
Innovation Project Manager, Display Unit 
Senior Project Manager (GMP - Life Science) 
Key Account Manager, Europe and Asia 
System Sales Development Consultant - Investment Projects, Merck Millipore 
Clinical Trial Manager